Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025:69:3-24.
doi: 10.1007/7854_2024_524.

Involvement of Complement in Alzheimer's Disease: From Genetics Through Pathology to Therapeutic Strategies

Nikoleta Daskoulidou  1 , Sarah M Carpanini  1 , Wioleta M Zelek  1 , B Paul Morgan  2
Affiliations
Review

Involvement of Complement in Alzheimer's Disease: From Genetics Through Pathology to Therapeutic Strategies

Nikoleta Daskoulidou et al. Curr Top Behav Neurosci. 2025.

Erratum in

Abstract

Complement is a critical component of innate immunity, evolved to defend against pathogens and clear toxic debris ranging from dead and dying cells to immune complexes. These roles make complement a key player in homeostasis; however, complement has a dark side. When the rigid control mechanisms fail, complement becomes dysregulated, acting as a driver of inflammation and resultant pathology in numerous diseases. Roles of complement in Alzheimer's disease (AD) and other dementias have emerged in recent years, supported by genetic, biomarker and pathological evidence and animal model studies. Numerous questions remain regarding the precise roles of complement in the brain in health and disease, including where and when complement is expressed, how it contributes to immune defence and garbage disposal in the healthy brain, and exactly how complement contributes to pathology in dementias. In this brief review, we will summarise current knowledge on complement roles in brain, present the evidence implicating complement in AD and explore whether complement represents an attractive therapeutic target for AD.

Keywords: Biomarkers; Brain; Complement; Dementia; Genetics; Synapse; Therapeutics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. ANX005 | ALZFORUM [Internet]. [cited 2024 Jun 17]. Available from: https://www.alzforum.org/therapeutics/anx005
    1. Apellis Pharmaceuticals, Inc. A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) [Internet]. clinicaltrials.gov ; 2024 Feb [cited 2024 Jan 1]. Report No.: NCT04579666. Available from: https://clinicaltrials.gov/study/NCT04579666
    1. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N et al (2022) New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 54(4):412–436 - PubMed - PMC
    1. Bilkei-Gorzo A (2014) Genetic mouse models of brain ageing and Alzheimer’s disease. Pharmacol Ther 142(2):244–257 - PubMed
    1. Bohlson SS, Tenner AJ (2023) Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation. Annu Rev Immunol 41:431–452 - PubMed

MeSH terms

Substances

LinkOut - more resources